Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccinesArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Ad26.COV2.S Ad26.COV2.S vaccine antibody B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta BNT162b2 BNT162b2 vaccine booster center contributed Control COVID-19 Delta dose Effectiveness elicited faster FIVE Gamma immunization moderate mRNA-1273 mRNA-based vaccine Mutation Neutralizing Neutralizing antibodies neutralizing antibody omicron P.1 postvaccination prevention Protein pseudovirus receiving recipient recommendation robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant subject Support vaccination Vaccine vaccine efficacy variants of concern variants of concern (VOCs). VoC VOCs wild type [DOI] 10.1002/jmv.28032 PMC 바로가기
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domainSARS-CoV-2 S2 도메인에 대한 항체의 결합 및 중화 능력Article Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody B.1.1.7 B.1.351 B.1.617.2 B.1.621 binding binding activity carried conserved convalescent patient coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 determined by domain ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence Immune escape immune protection mAb mAbs MERS MERS-CoV Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus molecular monoclonal antibodies monoclonal antibody N Terminal N terminal domain NAbs Neutralization assay neutralization assay. Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody NTD P.1 Protein pseudo-virus RBD Receptor binding domain reported Research respiratory Result S protein S proteins S2 protein S2 subunit SARS-CoV SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 S SARS-CoV-2 S2 SARS-CoV-2 WT Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly specific antibodies subunit target targets terminal Vaccine design variant variants wild-type [DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variantsArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] analysed B.1 B.1.617.2 BBIBP-CorV booster vaccination ChAdOx1-S Combination country COVID-19 elicited exhibited Gam-COVID-Vac greater Heterologous heterologous vaccination homologous immunized information mRNA-1273 mRNA-1273 vaccines Neutralizing Neutralizing antibodies non-replicative P.1 participant percentage Population protocol protocols provided SARS-CoV-2 second dose serum shortage significantly significantly lower vaccination Vaccination strategies Vaccination strategy Vaccine variant variants of concern. viral vector-based [DOI] 10.1016/j.vaccine.2022.10.021 PMC 바로가기
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamstersArticle Published on 2022-11-042022-11-15 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료기술, [키워드] Antigen B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta block Community COVID-19 vaccine current Delta delta variant detectable Efficacy eliminating expressed Fever Gamma hamster immunization Lineage Lung pathology maintain Neutralizing antibody response omicron P.1 pandemic predominant Prevent PROTECT SARS-CoV-2 strains SARS-CoV-2 variant sequence Spread titre Transmission Vaccine variants variants of concern vectored vaccine virus VoC VOCs [DOI] 10.1038/s41467-022-34439-7 PMC 바로가기
Genomic surveillance: Circulating lineages and genomic variation of SARS-CoV-2 in early pandemic in Ceará state, Northeast BrazilArticle Published on 2022-11-012022-11-16 Journal: Virus research [Category] SARS, 변종, 유전자 메커니즘, 치료기술, [키워드] B.1 B.1.1 B.1.1.28 B.1.1.33 Brazil circulating compose COVID-19 dataset death rate genetic diversity Genome Genome sequences genomes sequenced genomic genomic variation GISAID database impacted Lineage Missense Missense mutations Mutation mutations mutations. Other lineage P.1 P.2 pandemic polymorphism prevalent prevalent lineage SARS-CoV-2 SARS-CoV-2 sequencing sequence sequenced single-nucleotide SNPs Surveillance synonymous virus [DOI] 10.1016/j.virusres.2022.198908 PMC 바로가기
Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021Article Published on 2022-11-012022-11-16 Journal: Emerging Infectious Diseases [Category] SARS, 변종, [키워드] 95% CI acute respiratory syndrome Care coronavirus coronavirus disease COVID-19 dose Effectiveness Gamma Infection Long-term care mRNA vaccine occurred outbreak P.1 respiratory infections SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 United States USA Vaccine vaccine effectiveness variant viruses Washington zoonoses zoonoses. [DOI] 10.3201/eid2811.221043 PMC 바로가기
Conceptualising a channel-based overlapping CNN tower architecture for COVID-19 identification from CT-scan imagesArticle Published on 2022-10-282022-11-16 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 변종, [키워드] Accuracy AUC average B.1.1.7 CNN COVID COVID case COVID negative patient COVID-19 CT-scan dataset evaluate feature less lung Metrics mutated network Neural overlapping P.1 positive patient robust SARS-CoV-2 Tongji Hospital virus Wuhan, China [DOI] 10.1038/s41598-022-21700-8 PMC 바로가기
Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New JerseyArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, 치료기술, [키워드] acute respiratory syndrome antibody antibody resistance attack rate B.1.351 B.1.526 Care caused characteristic Clinical use collected Community Complete coronavirus COVID-19 Critical E484K mutation Evidence Examining exhibit exhibited hcp Health highlight individual infected individuals Infection Inpatient Lineage loss of activity monoclonal antibody Mutation N-terminal domain neutralization capacity Neutralizing antibody response neutralizing capacity New nosocomial NTD outbreak P.1 Patient plasma positive professional professionals proportion pseudovirus psychiatric facility Receptor binding domain reported reverse transcription robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant sera Spike protein Symptom symptomatic COVID-19 disease tested the SARS-CoV-2 the United State treat vaccinated individual vaccinated individuals vaccination Vaccine variant variants of concern variants of concern. VOCs wild type [DOI] 10.1128/mbio.02141-22 PMC 바로가기
Impact of Early Pandemic SARS-CoV-2 Lineages Replacement with the Variant of Concern P.1 (Gamma) in Western Bahia, BrazilArticle Published on 2022-10-212022-11-16 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, [키워드] addition affected age Brazil caused concern COVID-19 COVID-19 case COVID-19 cases death deaths disease epidemiological fluctuation Gamma Gender genetic variants Host Impact individual men nasopharynx P.1 pandemic Patient replaced replacement SARS-CoV-2 SARS-CoV-2 lineage significant increase study period symptomatic the patient the SARS-CoV-2 variant Variant of concern. Viral load VoC [DOI] 10.3390/v14102314 PMC 바로가기
RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challengeArticle Published on 2022-10-012022-11-15 Journal: Translational research : the journal of laboratory [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] amino acid change antibody B.1.1.529 B.1.1.7 B.1.1.7 lineage B.1.351 B.1.427 B.1.429 B.1.617.1 B.1.617.2 Beta Combination D614G mutation Delta disease severity domain E484K evaluated expressing Gamma greater highlight human-to-human transmission induce L452R Lineage lineages mice moderate mouse-adapted SARS-CoV-2 mRNA vaccine Multiple multiple mutations Mutation mutations N439K N501Y neutralization neutralized Neutralizing activity neutralizing antibody observation omicron other variant P.1 P681R pandemic PROTECT Protein pseudotyped pseudovirus reduced SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants serum antibody T478K the S protein Transmissibility vaccination Vaccine variant variants virulent [DOI] 10.1016/j.trsl.2022.04.007 PMC 바로가기